JapanTuberculosis profile
Population  2014 127 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.2 (2.1–2.3) 1.8 (1.7–1.8)
Mortality (HIV+TB only) 0.01 (<0.01–0.017) 0.01 (0–0.01)
Prevalence  (includes HIV+TB) 30 (12–54) 23 (9.8–43)
Incidence  (includes HIV+TB) 23 (20–26) 18 (16–21)
Incidence (HIV+TB only) 0.099 (0.083–0.12) 0.08 (0.07–0.09)
         
Case detection, all forms (%) 84 (75–96)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 0.7 (0.42–1.1) 9.8 (7.1–13)
MDR-TB cases among notified pulmonary
TB cases
100 (60–160) 95 (69–130)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 12 120   797
Pulmonary, clinically diagnosed 2 061   171
Extrapulmonary 4 255   211
       
Total new and relapse 19 615    
Previously treated, excluding relapses      
Total cases notified 19 615    
Among 19 615 new and relapse cases:
49 (<1%) cases aged under 15 years; male:female ratio: 1.6
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 7 861 (65%) 481 (41%) 8 442
Laboratory-confirmed RR-/MDR-TB cases     81
Patients started on MDR-TB treatment ***     56
TB/HIV 2014 Number (%)
TB patients with known HIV status 1 672 (9)
HIV-positive TB patients 45 (3)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013 (54) 15 941
Previously treated cases registered in 2013 (46) 1 008
HIV-positive TB cases, all types, registered in 2013 (40) 30
RR-/MDR-TB cases started on second-line treatment in 2012    
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 41
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-09-26 Data: www.who.int/tb/data